Introduction
Recent data indicate that vancomycin-resistant enterococci (VRE) are responsible for nearly 18% of all invasive enterococcal infections in North America. 1 Such infections have traditionally been associated with a poor prognosis. For example, in 1996, Edmond et al. 2 found mortality rates attributable to bacteremia with VRE approaching 40%. More recent data show that despite the introduction of antimicrobial agents effective against VRE, bacteremia still portends a poor prognosis. In 2000, Poduval et al. 3 found a 30% mortality rate in patients either infected or colonized with VRE admitted to an urban New York City hospital. Studies published in 2003 showed that surgical patients with VRE bacteremia had almost 40% mortality. 4, 5 In more recent studies, certain subgroups, such as patients with hematologic malignancies and neutropenic patients, had particularly poor outcomes with reported mortality rates surpassing 60%. 6, 7 While VRE bacteremia is associated with poor survival, only a minority of patients colonized with VRE actually go on to develop VRE bacteremia, although this risk seems to increase with immunosuppression. For example, fewer than 1% of VRE colonized nursing home residents develop VRE infection, while 13% of cancer patients and 11% of solid organ transplant recipients colonized with VRE go on to develop VRE infection. [8] [9] [10] However, this relatively low rate of progression from colonization to infection may not generalize to allogeneic hematopoietic stem cell transplant (AHSCT) recipients. Preliminary data from our institution, published in abstract form, demonstrate that the majority of the VRE colonized patients develop VRE infection with an associated mortality rate exceeding 80%. 11 On the basis of this observation in a limited number of patients, it appears that AHSCT recipients colonized with VRE may be at increased risk for mortality. Thus, we conducted a retrospective cohort study comparing clinical outcomes between VRE colonized and non-colonized patients undergoing AHSCT between 1998 and 2004.
Patients, materials and methods

Definition of terms
For definition of terms see Table 1 .
Study design
We received approval of institutional review board to conduct a minimally invasive, retrospective cohort study comparing post transplant outcomes between VRE colonized and non-colonized patients undergoing AHCST. The primary outcome was 100-day post transplant mortality. Secondary outcomes included (1) post transplant bacteremia-including all organisms and both VRE and vancomycin-susceptible enterococci bacteremia, (2) post transplant bleeding complications, (3) median time until engraftment, (4) median duration of initial hospitalization, (5) hepatic veno-occlusive disease, and (6) grades III and IV GVHD. Finally, as a secondary outcome, we also assessed for 100-day mortality stratified by year of transplantation.
Study population
Our study population was composed of consecutive adult patients undergoing AHSCT at the Mayo Clinic in Rochester, MN from March 1998 to December 2004. We identified these patients through the Mayo Clinic department of hematology AHSCT database.
All patients undergoing AHSCT had pretransplant perianal screening for VRE conducted through the Mayo Clinic's Infection Control program. All patients were screened at the time of hospital admission for transplant and twice weekly thereafter. Furthermore, all patients who had been previously admitted to the Mayo Clinic hematology unit (for example, for high-dose chemotherapy for their underlying disease) were screened twice weekly during those hospitalizations. Finally, all patients tested for Clostridium difficile toxins A and B during any admission were also screened for VRE. Perianal or stool screening for VRE consisted of culture analysis until 16 March 2004 when PCR testing became standard practice.
14 Patients colonized with VRE prior to transplantation were identified through a search of the Infection Control VRE database. Clinical data were collected through the Mayo Clinic electronic record system.
Sample size
A minimum sample size of 16 VRE colonized and 80 VRE non-colonized patients was determined, a priori, to be required to detect a difference of 30% mortality with 80% power and a two-sided a of 0.05.
Statistical analysis
Estimation of the a priori primary end point of 100-day mortality was performed using the Kaplan-Meier survival method. Overall 100-day mortality was also estimated stratified by method of screening (culture and PCR). The hazard ratio (HR) for VRE colonization in AHSCT recipients was first determined using univariate analysis. HRs were also calculated for variables found different at baseline between the two groups using univariate analysis. Multivariate analysis was used to determine the association between VRE colonization and mortality adjusted for differences in baseline variables between the two groups. A priori secondary end points were assessed using w 2 , Fisher's exact tests or non-parametric Wilcoxon rank-sum test, as appropriate. SAS 8.0 and JMP 5.1.2 statistical software (SAS Institute, Cary, NC, USA) were used to perform all tests (two-sided a ¼ 0.05). Grade III acute GVHD As per the modified Glucksberg staging system, any skin rash and diarrhea 41000 ml/day or bilirubin 43.1 mg per 100 ml 13 Grade IV acute GVHD As per the modified Glucksberg staging system, diffuse erythroedema and bulla formation or bilirubin 415 mg per 100 ml 13 Abbreviations: VOD ¼ veno-occlusive disease; VRE ¼ vancomycin-resistant enterococci; VSE ¼ vancomycin-susceptible enterococci.
Results
Study population
Two hundred and twenty-three adults underwent AHSCT at our institution during the study period. Two hundred and seventeen adults were included in the study. Four noncolonized patients were excluded for incomplete charting. Two colonized patients were excluded from the study. The first patient was found colonized 4 days after transplant. The second patient was colonized during the study period but was not transplanted until after the study period.
Recalculation of primary and secondary end points with those 6 patients included did not change the results. Of the 217 patients, 22 patients tested positive for VRE colonization prior to transplant, while 195 patients showed no evidence of pretransplant VRE colonization. Of the 22 colonized patients, 19 had a positive screening within 30 days of transplant. Diagnoses leading to AHSCT are presented in Table 2 .
Baseline characteristics
The colonized and non-colonized study arms shared many baseline clinical characteristics (Table 3) . Both groups had comparable mean ages and median times from diagnosis to transplant. In addition, liver, kidney, lung and heart functions at the time of transplant were similar. The frequency of pretransplant cytomegalovirus and herpes However, we observed six statistically significant differences in baseline variables in the cohort. Colonized patients were more likely to have had lower median platelet counts at day 0, to have an underlying diagnosis of AML, to have received Cy/TBI conditioning, to have had past episodes of acute renal failure, to have received a myoablative pretransplant conditioning regimen and to have had prior C. difficile-associated diarrhea (Table 3) .
Primary outcome
One hundred-day mortality was significantly higher for VRE colonized patients compared to non-colonized patients: 10 of 22 (45%) vs 50 of 195 (25%) patients, respectively (P ¼ 0.024) (Figure 1 ). Using univariate analysis, we found that patients colonized with VRE were twice as likely to die by day 100 post transplant compared to non-colonized patients (HR: 2.140, P ¼ 0.028, 95% confidence interval (CI): 1.085-4.220) ( Table 4) .
Since method of VRE colonization identification changed from culture to PCR in March 2004, we stratified our cohort by detection method. Although underpowered, the analysis revealed the difference in mortality between colonized and non-colonized patients to be statistically significant in the culture era (P ¼ 0.036) but not in the PCR era (P ¼ 0.070) (Figure 2 ).
Secondary outcomes
Colonized patients were significantly more likely to develop VRE bacteremia compared to non-colonized patients (6/22 patients (27%) vs 0/196 patients (0%); Pp0.01). There was no incidence of veno-occlusive disease or grade III to IV acute GVHD in colonized patients. Otherwise, both groups shared similar rates of overall post transplant bacteremia, bleeding complications, median time until engraftment and median time of initial hospitalization (Table 5) . Of the six colonized patients who developed bacteremia with VRE post transplant, five did not survive to day 100, despite treatment with antimicrobials active against VRE (Table 6 ). Of the remaining 16 colonized patients who did not become bacteremic with VRE, only five died by day 100 (31%). In comparison, non-colonized patients had a 100-day mortality rate of 25%.
Finally, survival analysis (graph not included) demonstrated no difference in 100-day mortality in our cohort of AHSCT recipients based on year of transplant (P ¼ 0.35).
Resolving baseline differences
Comparison of VRE colonized and non-colonized AHSCT recipients revealed six statistically significant differences in baseline variables which could have affected outcomeunderlying diagnosis of AML, Cy/TBI conditioning, history of acute renal failure, past history of C. difficileassociated diarrhea, platelet count, and intensity of pretransplant conditioning regimen. Univariate analysis showed that only platelet count at day 0 and intensity of pretransplant conditioning regimen were associated with increased 100-day mortality (Table 4) . Multivariate analysis showed that VRE colonized patients had poorer post transplant survival compared to non-colonized patients even after individually adjusting for the above-mentioned baseline differences, including platelet count and intensity of pretransplant conditioning regimen (Table 7 ). An underpowered analysis adjusting for all variables simultaneously showed that VRE colonization continued to be associated with 100-day mortality with an HR similar to those models using individual variables in the presence of VRE (Table 7) .
Discussion
In this study, we demonstrated an apparent association between pretransplant VRE colonization in AHSCT recipients and increased 100-day post transplant mortality.
The heterogeneity of our cohort did not appear to affect the outcome of our study. Many of the variables were similar between the two groups. Multivariate analysis demonstrated that baseline variables and surrogate markers found different at baseline (underlying diagnosis of AML, Cy/TBI conditioning, history of acute renal failure, past history of C. difficile-associated diarrhea, platelet count and intensity of conditioning regimen) did not confound the association between VRE colonization and 100-day post transplant mortality.
Importantly, pretransplant infectious disease variables such as previous bacteremia, presence of CMV IgG, C. difficile-associated diarrhea and vancomycin use did not appear to confound the association between colonization and mortality. This was also true for important baseline hematologic variables such as underlying diagnosis of AML, Cy/TBI conditioning regimen, donor HLA status and intensity of the conditioning regimen. Overall, the Table 6 Characteristics of post transplant VRE bacteremic patients association between VRE colonization and 100-day post transplant mortality persisted even in the presence of multiple potential confounders. Another important factor that could have confounded our results was the changes in clinical practice over the 6-year study period. To address this variable, we conducted a survival analysis looking at 100-day mortality based on year of transplantation. We found no difference in survival in our cohort (P ¼ 0.35).
The univariate outcomes of increased mortality with decreasing platelet counts were expected. The decreased survival associated with myeloablative conditioning regimens was consistent with past studies that suggested increased morbidity and non-transplant-related mortality for patients receiving myeloablative vs reduced-intensity conditioning regimens. 15, 16 The increased 100-day mortality in colonized patients appeared to be associated to VRE bacteremia. Of the six colonized patients who became bacteremic post transplant, five died within the first 100 post transplant days (83%), despite antimicrobial treatment effective against VRE. Of the remaining 16 colonized patients who did not become bacteremic with VRE, only five died by day 100 (31%), equivalent to the mortality rates of non-colonized patients (P ¼ 0.56).
These findings are consistent with the results presented in Weinstock et al. 17 who showed that AHSCT recipients bacteremic with VRE have a higher mortality rate than non-bacteremic patients (HR: 5.1; 95% CI: 1-26; P ¼ 0.05). In their study, all but one of the bacteremic patients died by day 100. 17 We could not find other outcomes to explain differences in mortality between the two groups. There were no cases of veno-occlusive disease or grade III or IV acute GVHD in our colonized group. (We did not assess for grade I or II acute GVHD, as they have not been shown to adversely impact 100-day mortality. 18, 19 ) Assessment of the remaining secondary end points that may have influenced post transplant mortality (overall post transplant bacteremia, bleeding complications and the surrogate markers for poor initial outcome-days until engraftment and days hospitalized initially post transplant) revealed no differences between the two groups.
Our results depart from those of Dubberke et al. 20 and Avery et al. 21 who found that despite elevated mortality rates in AHSCT recipients bacteremic with VRE, few deaths were directly attributable to the bacteremia. However, those studies were conducted without control groups. Also both groups of authors acknowledged that VRE bacteremia may have contributed to the complications leading to death.
In our cohort, excess deaths in the colonized group were associated with VRE bacteremia. However, we cannot conclusively state that VRE bacteremia was responsible for cause of death as many of the patients who died with VRE bacteremia had multiple severe coexisting conditions. Bacteremia may have been the final insult in an exceedingly fragile population.
Our results suggest that gastrointestinal bacterial colonization plays an important role in the development of bacteremia in this cohort. Gut translocation of pathogenic organisms has been noted in other disease states and in a variety of circumstances, including after administration of chemotherapy in animal models. [22] [23] [24] [25] [26] [27] [28] Given the immunosuppressive conditioning regimens (for example, chemotherapy, TBI) administered to our patient population, we hypothesize a similar risk of translocation of gastrointestinal VRE in AHSCT. Furthermore, while all stem cell recipients at our institution receive a standard protocol of prophylactic anti-infective agents (including a quinolone, penicillin and an antifungal medication at time of transplantation), the coverage of such regimens does not extend to VRE. Theoretically, this could increase VRE density in the gastrointestinal tract, potentially increasing the risk of translocation and eventual infection. 29 The VRE bacteremic patients in our study had a short time between identification of colonization prior to transplant and bacteremia. All six patients had a positive screen within 30 days of transplant and five developed VRE bacteremia within 18 days of transplant.
After identification of VRE in blood cultures, all six bacteremic patients in our study promptly received antimicrobials effective against VRE (for example, linezolid, quinupristin/dalfopristin). However, this did not appear to alter outcomes. Five patients died despite treatment, and four within 2 weeks of their first positive blood culture. These findings parallel those of Weinstock et al., 17 Dubberke et al. 20 and Avery et al., 21 which demonstrated high mortality among VRE bacteremic patients despite treatment with linezolid, daptomycin, quinupristin/dalfopristin or chloramphenicol.
In light of the high progression rate of colonization to bacteremia shortly after transplant, the high mortality rate associated with bacteremia and the poor outcomes with current antimicrobial regimens, investigations into temporary suppression of VRE colonization at time of transplant are warranted. Wong et al. 30 demonstrated temporary suppression of gastrointestinal VRE colonization with the non-absorbable glycolipodepsipeptide ramoplanin. Other alternatives include the addition of a systemic anti-VRE Table 7 Multivariate analysis showed that VRE colonized patients had poorer survival compared to non-colonized patients after adjusting for statistically significant baseline differences agent (linezolid, daptomycin) to the peritransplant prophylactic regimen. However, such intervention in this population needs to be carefully considered, as resistance to newer antimicrobials active against VRE has been reported, 31, 32 and myelosuppression is a known adverse effect of linezolid. 33 Unfortunately, at this point we cannot predict risk factors for the progression of colonization to bacteremia. Our study was performed with a small cohort of colonized patients (n ¼ 22). However, investigation of a larger cohort of colonized patients may provide clues.
In the final 9 months of the study, VRE screening changed from a culture-to a PCR-based method. Although this did not bias our study, as both groups were screened with a systematically similar method, this change in technique may have led to imprecision (widening of the CIs) in our results. While colonized patients had decreased 100-day survival compared to non-colonized patients when using culture screening techniques, the difference was not statistically significant with PCR screening (Figure 2) . As only seven patients were found to be VRE positive using PCR in the last 9 months of the study, a larger study will be needed to better assess the association between VRE colonization identified through PCR and post transplant mortality. Such a study would be quite relevant, as PCR has a higher sensitivity than culture in detecting VRE, allowing identification of lower bacterial loads as compared to culture techniques.
14 Theoretically, patients with lower gastrointestinal bacterial loads may be less likely to proceed to VRE infection.
Our study has several limitations. As previously mentioned, it was not powered to assess all important variables simultaneously in multivariate analysis. Also, we powered our study to find a 30% difference in mortality by day 100. However, the absolute difference in mortality was actually 20%. Also, we did not collect data to assess the association between colonization and previous Mayo hematology admissions. It is possible that the more intensive screening associated with hematology admissions is associated with a greater likelihood of obtaining a VRE-positive outcome. Thus, some patients not hospitalized on the Mayo hematology unit may have been falsely classified as not colonized. This may be more problematic with culture method of detection compared to PCR method which detects much lower loads of VRE. Subgroup analysis, although underpowered, showed mortality rates in the PCR era similar to the rates in culture era ( Figure 2) . Next, as AHSCT recipients represent a heterogenous population of patients, we could not investigate all pretransplant risk factors, which could have influenced outcome. However, the surrogate markers chosen for comparison encompassed many variables and risk factors, which could have led to bias or confounding. Next, the precision of our results is decreased by the use of two diagnostic criteria and the presence of only seven colonized patients during the PCR era. A larger study is needed to assess the prognostic role of PCR in VRE colonization. Furthermore, like all observational studies, our study lacks blinding and randomization, which can lead to increased susceptibility to bias. Also, our results are not generalizable to other populations. As previously mentioned, progression rates of colonization to bacteremia and mortality rates for VRE bacteremia vary between different cohorts. For example, VRE colonization only infrequently proceeds to infection and death in pediatric AHSCT recipients. 34 Also the outcomes of VRE colonization may be different at institutions that use a BU/Cy conditioning regimen more frequently.
In summary, colonization with VRE prior to AHSCT appears to be associated with 100-day post transplant mortality. This association endures after adjusting for important baseline variables, which could influence outcome. The increase in mortality appears to be related to VRE bacteremia. The reliability of our results is weakened by the use of two methods to detect colonization and the limited number of patients in our colonized group. Future studies will need to assess the association between temporary suppression of VRE colonization and post transplant mortality, the role of PCR as a prognostic tool in VRE colonization and the risk factors of progressing from colonization to bacteremia.
